PAMELA STAVE: Open Payments
NPI 1669556239 · LANSING, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$900 in 19 payments from 12 companies in 2025. Trend: 2023 $70 · 2024 $616 · 2025 $900
Food & beverage: $816Education: $84
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 5 | $276 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $123 |
| Aimmune Therapeutics, Inc. | 1 | $120 |
| Ipsen Biopharmaceuticals, Inc | 2 | $120 |
| Gilead Sciences, Inc. | 1 | $100 |
| Madrigal Pharmaceuticals | 2 | $46 |
| Azurity Pharmaceuticals, Inc. | 1 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| Lilly USA, LLC | 1 | $19 |
| Ardelyx, Inc. | 1 | $19 |
Products named: TREMFYA, ENTYVIO, ZENPEP, IQIRVO, Livdelzi, REZDIFFRA, SUTAB, DUPIXENT.
Industry payments across MI — which companies pay providers there.
